ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

MLTX MoonLake Immunotherapeutics

45.26
2.69 (6.32%)
May 03 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
MoonLake Immunotherapeutics MLTX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
2.69 6.32% 45.26 19:00:00
Open Price Low Price High Price Close Price Previous Close
43.51 43.405 45.465 45.26 42.57
more quote information »

Recent News

Date Time Source Heading
4/10/202406:00BWMoonLake Immunotherapeutics Inks Three-Year Technology..
3/11/202407:01EDGAR2Form 8-K - Current report
3/10/202411:00GLOBEMoonLake announces significant improvements with Nanobody®..
3/04/202407:00GLOBEMoonLake Immunotherapeutics to present MIRA trial data of..
2/29/202418:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/29/202418:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/29/202407:05EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
2/29/202407:03EDGAR2Form 8-K - Current report
2/29/202407:00GLOBEMoonLake Immunotherapeutics Reports Full Year 2023 Financial..
2/26/202408:00EDGAR2Form 8-K - Current report
2/26/202407:00GLOBEMoonLake Immunotherapeutics Announces Positive Feedback from..
2/23/202415:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/22/202417:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/20/202417:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/16/202417:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
2/15/202415:02EDGAR2Form 144 - Report of proposed sale of securities
2/15/202407:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/14/202415:05EDGAR2Form 144 - Report of proposed sale of securities
12/21/202315:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/20/202315:16EDGAR2Form 144 - Report of proposed sale of securities
12/19/202315:34EDGAR2Form 144 - Report of proposed sale of securities
11/14/202307:00GLOBEMoonLake Immunotherapeutics Reports Third Quarter 2023..
11/06/202306:55EDGAR2Form 8-K - Current report
11/05/202310:00GLOBEMoonLake Immunotherapeutics announces landmark Phase 2..
10/16/202305:16EDGAR2Form 8-K - Current report
10/15/202308:03GLOBEMoonLake Immunotherapeutics announces the full dataset from..
10/11/202309:15GLOBEMoonLake Immunotherapeutics presents positive 12-week data..
10/04/202306:01GLOBEPhase 2 MIRA primary analysis trial results (12-week) for..
9/06/202306:00GLOBEMoonLake Immunotherapeutics to host a Capital Markets Day on..
8/10/202306:00GLOBEMoonLake Immunotherapeutics Reports Second Quarter 2023..
7/25/202307:00GLOBEMoonLake completes patient randomization ahead of schedule..
7/17/202306:30IHMARKETNEWSMonday’s Wall Street Highlights: Microsoft, Santander,..
6/28/202304:00GLOBEMoonLake Immunotherapeutics Announces Pricing of $400..
6/26/202315:01GLOBEMoonLake Immunotherapeutics Announces Proposed Underwritten..
6/25/202308:00GLOBEMoonLake Immunotherapeutics achieves landmark milestone with..
5/12/202306:45GLOBEMoonLake Immunotherapeutics Reports First Quarter 2023..

Your Recent History

Delayed Upgrade Clock